We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is GEHC a Buy Now as Growth Improves but Execution Risks Persist?
Read MoreHide Full Article
Key Takeaways
GEHC trades at 14.27X forward earnings, below its five-year median of 17.25X and sub-industry at 17.76X.
GE HealthCare posted 5% organic growth in Advanced Imaging and 14.6% growth in Pharmaceutical Diagnostics.
GEHC faces PCS weakness, $250M of expected 2026 inflation and $10.1B in debt after the Intelerad deal.
GE HealthCare Technologies Inc. (GEHC - Free Report) offers investors a mixed setup. Growth is improving in imaging and diagnostics, backlog remains elevated and valuation is below key benchmarks, but execution pressure in Patient Care Solutions and a heavier debt load limit the margin for error.
That balance argues for selectivity rather than chasing the recent operating momentum. The upside case depends on converting orders, scaling recurring businesses and offsetting inflation without allowing PCS weakness to dilute broader gains.
GEHC’s Valuation Offers a Potential Entry Point
GEHC trades at 14.27X forward 12-month earnings, below the Medical-Products sub-industry at 17.76X and its five-year median of 17.25X. That discount leaves room for rerating if earnings growth and margins improve.
Over the past five years, the stock has traded between 11.49X and 23.18X forward earnings. The current multiple therefore sits below the midpoint of its longer-term valuation range, but execution still matters.
Image Source: Zacks Investment Research
GE HealthCare Has Multiple Growth Engines
Advanced Imaging Solutions generated 5% organic revenue growth in the second quarter, while Pharmaceutical Diagnostics grew 14.6%. New imaging platforms, AI-enabled products, contrast-media demand and radiopharmaceutical adoption provide several growth avenues.
For industry context, Koninklijke Philips N.V. (PHG - Free Report) is advancing a 2026-2028 health-technology plan, while Medtronic plc (MDT - Free Report) continues introducing AI-enabled medical systems. Their innovation activity underscores the competitive intensity across medtech.
GEHC’s Recurring Revenue Mix Is Strengthening
Flyrcado, Vizamyl, contrast media, software and services can increase GEHC’s recurring-revenue exposure. Management targets more than $500 million in annual Flyrcado revenues and more than $200 million from Vizamyl by 2028.
Intelerad adds enterprise imaging software across hospital and outpatient settings, while AI-enabled software upgrades can also be offered through subscription models. A larger recurring mix could make growth less dependent on one-time equipment sales.
GE HealthCare’s Execution Risks Remain Significant
Patient Care Solutions remains the weakest segment. Second-quarter revenues fell 13.3%, segment EBIT was negative and operational fulfillment problems weighed on results, although first-half orders improved.
Inflation also remains a meaningful constraint. Management continues to expect about $250 million of 2026 inflation tied to memory chips, oil, freight and other components, increasing the importance of pricing, productivity and backlog conversion.
GE HealthCare ended the second quarter with $2.1 billion in cash and cash equivalents and $10.1 billion in debt after closing the $2.3 billion Intelerad acquisition in March.
Inventories rose to $2.48 billion at June 30 from $2.23 billion at year-end 2025. With second-quarter free cash flow at $68 million, integration discipline and working-capital execution are important to preserving capital-allocation flexibility.
GEHC’s Ratings Favor Selectivity Over Chasing Growth
GEHC has credible growth drivers and a valuation discount, but PCS weakness, inflation and leverage keep the investment case from being one-sided. The stock’s current setup favors a measured approach rather than an aggressive chase.
GEHC carries a Zacks Rank #2 (Buy). Its Value Score of B supports the valuation case, but the Growth Score of D, Momentum Score of F and VGM Score of C show that favorable near-term rank signals are not matched by uniformly strong style characteristics. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
View the Zacks #1 Rank List
Image: Bigstock
Is GEHC a Buy Now as Growth Improves but Execution Risks Persist?
Key Takeaways
GE HealthCare Technologies Inc. (GEHC - Free Report) offers investors a mixed setup. Growth is improving in imaging and diagnostics, backlog remains elevated and valuation is below key benchmarks, but execution pressure in Patient Care Solutions and a heavier debt load limit the margin for error.
That balance argues for selectivity rather than chasing the recent operating momentum. The upside case depends on converting orders, scaling recurring businesses and offsetting inflation without allowing PCS weakness to dilute broader gains.
GEHC’s Valuation Offers a Potential Entry Point
GEHC trades at 14.27X forward 12-month earnings, below the Medical-Products sub-industry at 17.76X and its five-year median of 17.25X. That discount leaves room for rerating if earnings growth and margins improve.
Over the past five years, the stock has traded between 11.49X and 23.18X forward earnings. The current multiple therefore sits below the midpoint of its longer-term valuation range, but execution still matters.
Image Source: Zacks Investment Research
GE HealthCare Has Multiple Growth Engines
Advanced Imaging Solutions generated 5% organic revenue growth in the second quarter, while Pharmaceutical Diagnostics grew 14.6%. New imaging platforms, AI-enabled products, contrast-media demand and radiopharmaceutical adoption provide several growth avenues.
For industry context, Koninklijke Philips N.V. (PHG - Free Report) is advancing a 2026-2028 health-technology plan, while Medtronic plc (MDT - Free Report) continues introducing AI-enabled medical systems. Their innovation activity underscores the competitive intensity across medtech.
GEHC’s Recurring Revenue Mix Is Strengthening
Flyrcado, Vizamyl, contrast media, software and services can increase GEHC’s recurring-revenue exposure. Management targets more than $500 million in annual Flyrcado revenues and more than $200 million from Vizamyl by 2028.
Intelerad adds enterprise imaging software across hospital and outpatient settings, while AI-enabled software upgrades can also be offered through subscription models. A larger recurring mix could make growth less dependent on one-time equipment sales.
GE HealthCare’s Execution Risks Remain Significant
Patient Care Solutions remains the weakest segment. Second-quarter revenues fell 13.3%, segment EBIT was negative and operational fulfillment problems weighed on results, although first-half orders improved.
Inflation also remains a meaningful constraint. Management continues to expect about $250 million of 2026 inflation tied to memory chips, oil, freight and other components, increasing the importance of pricing, productivity and backlog conversion.
GEHC’s Balance Sheet Reduces Financial Flexibility
GE HealthCare ended the second quarter with $2.1 billion in cash and cash equivalents and $10.1 billion in debt after closing the $2.3 billion Intelerad acquisition in March.
Inventories rose to $2.48 billion at June 30 from $2.23 billion at year-end 2025. With second-quarter free cash flow at $68 million, integration discipline and working-capital execution are important to preserving capital-allocation flexibility.
GEHC’s Ratings Favor Selectivity Over Chasing Growth
GEHC has credible growth drivers and a valuation discount, but PCS weakness, inflation and leverage keep the investment case from being one-sided. The stock’s current setup favors a measured approach rather than an aggressive chase.
GEHC carries a Zacks Rank #2 (Buy). Its Value Score of B supports the valuation case, but the Growth Score of D, Momentum Score of F and VGM Score of C show that favorable near-term rank signals are not matched by uniformly strong style characteristics. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.